Sponsors (2)
The bill creates a clearer regulatory category and labeling/GMP requirements for homeopathic products—improving predictability and some product standards—but does so while exempting those products from the FDA's usual premarket safety/efficacy reviews and certain testing and enforcement, increasing risks that consumers may face ineffective or inconsistently potent products.
Buyers of retail homeopathic products will see a clear, prominent statement that the product's uses have not been evaluated by FDA and that it is for traditional homeopathic uses, improving upfront disclosure when making purchase decisions.
Regulators, manufacturers, and stakeholders gain a clarified statutory framework, an official regulatory category, and a permanent advisory committee, making enforcement, compliance, and stakeholder input more predictable.
Manufacturers will have to meet new FDA good manufacturing practice (GMP) and labeling rules within three years, which should improve product quality, consistency, and reduce some uncertainty about safety and availability.
People who use homeopathic products will not be protected by the FDA's standard premarket safety and efficacy review because the bill bars applying the new-drug approval process (section 505) and generally limits FDA's ability to require full drug-review evidence.
Consumers may be exposed to products with unknown or inconsistent potency because homeopathic products are exempted from required laboratory identity and strength testing.
People shopping for treatments could be misled because the bill permits claims supported by 'traditional homeopathic principles' and allows phrasing like 'Traditionally used for,' which can imply effectiveness comparable to evidence-based therapies.
Based on analysis of 3 sections of legislative text.
Creates a statutory regulatory category for homeopathic drug products, requires FDA GMP and labeling rules, sets testing and labeling rules, creates an advisory committee, and rescinds 2022 FDA guidance.
Official title: Amend the Federal Food, Drug, and Cosmetic Act with respect to homeopathic drug products, and for other purposes.
Introduced June 4, 2026 by Thomas Hawley Tuberville · Last progress June 4, 2026
Creates a statutory regulatory category for "homeopathic drug products," defining the term in the FD&C Act, establishing special labeling, manufacturing, testing, and claims rules, and requiring the FDA to issue GMP and labeling regulations within three years. The bill creates a temporary Homeopathic Drug Product Advisory Committee, prohibits using the standard new drug approval pathway for these products, amends misbranding rules to prevent misuse of the term "homeopathic," and rescinds the FDA's December 7, 2022 guidance on homeopathic products.